Dear Colleague,

The Metabolic Syndrome is a greater detriment than cancer to our society’s overall health. In order to address this problem, there has been an increasing effort to find solutions that prevent and reverse the Metabolic Syndrome.

The 4th Metabolic Diseases World Summit, taking place on November 6-7, 2008 in Boston, MA, is devoted to better understanding new options in dealing with this condition. Speakers from both academia and industry will focus on the advances of treatments for Metabolic Diseases and how they relate to Insulin, Diabetes, Obesity, Cardiovascular Disease and Mitochondrial Function.

 Save up to up $300 by September 6, 2008! Register now!

SEND YOUR TEAM...Register 2, and the 3rd person goes FREE!
 
 

HIGHLIGHTS


•  Panel Discussions:
- Partnering/Licensing in Metabolic Diseases

- Regulatory Issues in Metabolic Disease Drug Development

•  Keynote Speeches:
- Epidemiology and Medical Needs of the Metabolic Syndrome

- FDA Regulations, Draft Guidelines, & Getting Therapies to Market
 
Abstract Submissions:
 Submit an abstract for poster presentation and have the chance to give an oral presentation. Deadline is October 6, 2008. Click here for submission.

UPCOMING EVENTS

Protein Therapeutics Discovery & Development
September 8-9, 2008
San Diego, CA
Bugs & Drugs
September 22-23, 2008
San Diego, CA
Global Clinical Trial Operations
September 25-26, 2008
San Diego, CA
Biomarker Discovery Europe
 Oct. 2-3, 2008
Dublin, Ireland
 10% discount by Sept 2

 4th Neurodegenerative Diseases Drug Discovery
 Oct. 9-10, 2008
San Francisco, CA
 10% discount by Sept 9

4th Modern Drug Discovery and Development Summit
 6 Full Tracks
3 Short Symposia
6 Study Sessions
Oct. 15-17, 2008
San Diego, CA

 Advances in Stem Cell Discoveries
Oct. 27-28, 2008
San Francisco, CA
 10% discount by Sept 27

 4th Metabolic Diseases World Summit
Nov. 6-7, 2008
Boston, MA
 20% discount by Sept 6

 6th Vaccines: All Things Considered
 Nov. 13-14, 2008
Washington, DC
 20% discount by Sept 12
 

PROGRAM HIGHLIGHTS


Metabolic Syndrome: Delaying CVD and Type 2 Diabetes
•  Risk Factors and Complications: Hyperglycemia, Insulin Resistance
   and Cardiovascular Diseases
•  Current Treatments to Reduce Cardiovascular Risks
•  Current Treatments of Type 2 Diabetes (including Insulin Sensitizers):
    What Has Worked and What are the Unmet Needs?

Obesity: New Therapeutic Targets
•  MCHR-1
 •  11-Beta – HSD - Incyte Obesity Drug Therapies
•  SCD1
•  Ghrelin Antagonists
•  AMPK - Obesity and Diabetes
 
 Diabetes: New Therapeutic Targets
•  GLP-1 Analogs
•  GPR – 119 – H Overton Prosidion
•  Glucokinase Activators
•  SGLT2
•  DPPIV Inhibitors
•  FGF21
•  Sirt1
•  Mitochondrial Dysfunction and Diabetes
•  Endoplasmic Reticulum Stress and Diabetes

Obesity: Drug Development
•  Obesity Drug Therapies Orexigen (Contrave and Empatic Phase III and
    II), Arena (Lorcaserin Phase III), Neurosearch (Tesofensin Phase IIb), 
   (Taranabant)
 •  Combination Drug Therapies vs. Single Drug Therapies
•  CBI Antagonists Rimonabant
 
Diabetes: Drug Development
•  Strengths and Weaknesses of Current and Existing Drugs
•  Anti-Diabetic Drugs in Development
•  Avandia Cardiovascular Safety Data
•  SGLT2
•  GKAs
•  GLP-1 Analogs – Byetta LAR Data
•  The Success of Januvia Development
•  The Failure of the Torcetrapib Development on Potential MOAs

[FULL AGENDA]
 

DISTINGUISHED PRESENTERS & ADVISORS


Ganesh Bhat, Group Leader, Genomics Inst.of the Novartis Res. Fdn.
Brad Geddes, Director, Elixir Pharmaceuticals, Inc.
Joe Grimsby, Senior Research Leader, Roche
Yanglin He, Research Scientist, Novartis
Timothy Herpin, Assoc. Dir., Scientific Licensing, Bristol-Myers Squibb
Mike Jirousek, CSO, Catabasis Pharmaceuticals, Inc.
Sotirios Karathanasis, Vice President, Bioscience, AstraZeneca
Alex Kharontonnekov, Research Advisor, bioTDR, Eli Lilly & Co.
Yang Li, Research Scientist, Amgen
John Mayer, Senior Research Advisor, Eli Lilly & Co.
Michael McCully, Director & Senior Analyst, Recombinant Capital
Ram Pillarisetti, Vice President of Research, Reddy US Therapeutics
Cristina Rondinone, Director, Research Metabolic Diseases, Roche
Ming Wang, Scientific Director, Amgen
Bernice Welles, Vice President Development, DIObex
Ruojing Yang, Senior Research Biologist, Merck & Co. Inc.

[Speaker List]

 

For Business Development & Exhibiting opportunities, contact Josette Barba at 626-256-6405 x105 or via email at josette.barba@gtcbio.com 

This advertisement comes to you from GTCbio, 434 W. Foothill Blvd, Monrovia, CA 91016. To update your contact information, please click here. If you prefer not to receive further messages from this sender, please send an email to remove@gtcbio.com. Please make sure to remove the forwarding email address and any email alias.